Mind the gap: Inequalities in mental health care and lack of social support in Parkinson disease.

Inequalities in mental healthcare and lack of social support during the COVID-19 pandemic have lowered quality of life and increased overall burden of disease in people with Parkinson's (PWP). Although the pandemic has brought attention to these inequalities, they are long standing and will persist unless addressed. Lack of awareness of mental health issues is a major barrier and even when recognized disparities based on race, gender, and socioeconomic factors limit access to already scarce resources. Stigma regarding mental illness is highly prevalent and is a major barrier even when adequate care exists. Limited access to mental healthcare during the pandemic and in general increases the burden on caregivers and families. Historically, initiatives to improve mental healthcare for PWP focused on interventions designed for specialty and academic centers generally located in large metropolitan areas, which has created unintended geographic disparities in access. In order to address these issues this point of view suggests a community-based wellness model to extend the reach of mental healthcare resources for PWP.

A comparative study of cardiac involvement of kawasaki disease and multisystem inflammatory syndrome post COVID (MISC) in children

Background and Aim: Kawasaki Disease remains an enigma to the world to this day since first described by Dr. Tomisaku Kawasaki in 1967. In the last half a century there has been wide-spread global research elaborating the clinical aspects and patho-genesis of this disease entity. Multisystem Inflammatory Syndrome post Covid (MISC) is a relatively new disease which was described in literature in mid 2020. The striking resemblance as well as differences in spectrum of cardiac involvement of both the conditions has been elaborated in this study from a tertiary care centre in Eastern India. Method(s): The study was conducted over a period of 3 years from June 2018 to June 2021. Fiftyone patients with Kawasaki disease (including atypical and incomplete cases) and sixty children diag-nosed with MISC were included in the study. Echocardiography details were noted by a single observer. Data regarding the patient particulars, clinical aspects, lab parameters, imaging details and treatment particulars were collected and analysed. Patients were followed up for a minimum period of six months to one year. Result(s): In the Kawasaki group(51), infants(20) presented with multiple (and larger) aneurysms. Older children (gt;5 years) had more of single coronary involvement, (mostly LAD) and also had more atypical presentation(18) associated with infections like Dengue, Staphylococcal infection, Scrub Typhus. There were 4 cases of Kawasaki shock syndrome, all below 5 years. In the MISC group (60), there was also multiple coronary involvement in infants (11). But LV dysfunction was more common in older children and adolesecents (20), of whom 18 (90%) presented with severe dysfunction (LVEFlt;35%). Those with coronary involve-ment had normal function and those with dysfunction had no coronary involvement. Mild to moderate aneurysmal dilation of coronaries was found in children one to five years of age. No giant aneurysm was found in MISC. Overall, LMCA with LAD was the commonest pattern of involvement in both the conditions. Conclusion(s): KD and MISC had similar pattern of coronary involve-ment, but absence of giant aneurysm and significantly severe dys-function in older children in MISC indicates a likely different pathogenesis for myocardial involvement in MISC.

Depression, anxiety and PTSD symptoms before and during the COVID-19 pandemic in the UK.

BACKGROUND: The impact of the coronavirus disease 2019 (COVID-19) pandemic on mental health is still being unravelled. It is important to identify which individuals are at greatest risk of worsening symptoms. This study aimed to examine changes in depression, anxiety and post-traumatic stress disorder (PTSD) symptoms using prospective and retrospective symptom change assessments, and to find and examine the effect of key risk factors. METHOD: Online questionnaires were administered to 34 465 individuals (aged 16 years or above) in April/May 2020 in the UK, recruited from existing cohorts or via social media. Around one-third (n = 12 718) of included participants had prior diagnoses of depression or anxiety and had completed pre-pandemic mental health assessments (between September 2018 and February 2020), allowing prospective investigation of symptom change. RESULTS: Prospective symptom analyses showed small decreases in depression (PHQ-9: -0.43 points) and anxiety [generalised anxiety disorder scale - 7 items (GAD)-7: -0.33 points] and increases in PTSD (PCL-6: 0.22 points). Conversely, retrospective symptom analyses demonstrated significant large increases (PHQ-9: 2.40; GAD-7 = 1.97), with 55% reported worsening mental health since the beginning of the pandemic on a global change rating. Across both prospective and retrospective measures of symptom change, worsening depression, anxiety and PTSD symptoms were associated with prior mental health diagnoses, female gender, young age and unemployed/student status. CONCLUSIONS: We highlight the effect of prior mental health diagnoses on worsening mental health during the pandemic and confirm previously reported sociodemographic risk factors. Discrepancies between prospective and retrospective measures of changes in mental health may be related to recall bias-related underestimation of prior symptom severity.

Viruses, parkinsonism and Parkinson's disease: the past, present and future.

Parkinsonism secondary to viral infections is not an uncommon occurrence and has been brought under the spotlight with the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A variety of viruses have been described with a potential of inducing or contributing to the occurrence of parkinsonism and Parkinson's disease (PD), although the relationship between the two remains a matter of debate originating with the description of encephalitis lethargica in the aftermath of the Spanish flu in 1918. While some viral infections have been linked to an increased risk for the development of PD, others seem to have a causal link with the occurrence of parkinsonism. Here, we review the currently available evidence on viral-induced parkinsonism with a focus on potential pathophysiological mechanisms and clinical features. We also review the evidence on viral infections as a risk factor for developing PD and the link between SARS-CoV-2 and parkinsonism, which might have important implications for future research and treatments.

Movement disorders in COVID-19 times: impact on care in movement disorders and Parkinson disease.

PURPOSE OF REVIEW: The purpose of this review is to outline the impact of the COVID-19 pandemic on movement disorder holistic care, particularly in the care of people with Parkinson disease (PWP). RECENT FINDINGS: As the pandemic unfolds, a flurry of literature was published regarding the impact of COVID-19 on people with Parkinson disease including the direct impact of infection, availability of ambulatory care, loss of community-based team care, and acceptability of telemedicine. SUMMARY: COVID-19 has impacted the care of PWP in numerous ways. Recognizing infection in PWP poses challenges. Specific long-term complications, including emerging reports of long COVID syndrome is a growing concern. Caregivers and PWP have also been impacted by COVID-19 social isolation restrictions, with radical changes to the structure of social networks and support systems globally. In a matter of weeks, the global community saw an incredible uptake in telemedicine, which brought benefits and pitfalls. As PWP adapted to virtual platforms and the changing architecture of care delivery, the pandemic amplified many preexisting inequities amongst populations and countries, exposing a new 'digital divide'.

Opicapone OCEAN study in Parkinson's: Design of a randomized double-blind placebo-controlled trial

Background and aims: Opicapone (OPC) proved to be effective in the treatment of end-of-dose motor fluctuations in Parkinson's Disease (PD) patients [1,2]. End-of-dose motor fluctuations and associated pain are commonly observed in PD patients on L-dopa/DOPA decarboxylase inhibitors (DDCI). They have a detrimental impact on the quality-of-life [3] and are in part mediated via dopaminergic pathways. [4]. Therefore, an a-priori presumption was made that OPC will overcome end-of-dose fluctuation related pain and consequently improve patients' well-being. Methods: Patients (30 years old) with idiopathic PD, treated with three to eight daily oral doses of L-dopa/DDCI and with 'wearing-off' (end-of-dose deterioration) phenomenology, and experiencing PD associated pain will be randomised (1:1) to OPC 50mg once-daily or placebo during a 24-week evaluation-period (Figure 1). To detect a minimum clinically relevant magnitude of effect between arms, 70 subjects per group is necessary. Results: The primary endpoint is change from baseline in Domain 3 (fluctuation-related pain) of King's-Parkinson's- Disease-Pain-Scale (KPPS). Secondary endpoints include tolerability, functional motor and non-motor assessments (KPSS, MDS-NMS, PDQ-8, Hauser's home diary), and Global Impression of Change (CGI-C, PGI-C). Study sites are in Germany, Italy, Portugal, Spain and UK. First-patient-in is expected for 2021 and Last-patient-out to late 2022. Timelines might be impacted by COVID-19 pandemic situation. Conclusion: This study will further evaluate the impact of 50mg opicapone once daily as adjunctive therapy to L-dopa/ DDCI on fluctuation-associated pain. (Figure Presented).

The impact of COVID-19 on palliative care for people with Parkinson's and response to future pandemics.

Introduction: Although in some countries, palliative care (PC) still remains poorly implemented, its importance throughout the course of Parkinson's disease (PD) is increasingly being acknowledged. With an emergence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic, growing emphasis has been placed on the palliative needs of people with Parkinson's (PwP), particularly elderly, frail, and with comorbidities.Areas covered: The ongoing COVID-19 pandemic poses an enormous challenge on aspects of daily living in PwP and might interact negatively with a range of motor and non-motor symptoms (NMS), both directly and indirectly - as a consequence of pandemic-related social and health care restrictions. Here, the authors outline some of the motor and NMS relevant to PC, and propose a pragmatic and rapidly deployable, consensus-based PC approach for PwP during the ongoing COVID-19 pandemic, potentially relevant also for future pandemics.Expert opinion: The ongoing COVID-19 pandemic poses a considerable impact on PwP and their caregivers, ranging from mental health issues to worsening of physical symptoms - both in the short- and long-term, (Long-COVID) and calls for specific, personalized PC strategies relevant in a lockdown setting globally. Validated assessment tools should be applied remotely to flag up particular motor or NMS that require special attention, both in short- and long-term.

A Preliminary Investigation of the Views of People With Parkinson's (With and Without Psychosis) and Caregivers on Participating in Clinical Trials During the Covid-19 Pandemic: An Online Survey.

Background: The coronavirus pandemic is having a profound impact on non-COVID-19 related research, including the delivery of clinical trials for patients with Parkinson's disease. Objectives: A preliminary investigation to explore the views of Parkinson's disease (PD) patients, with and without experience of psychosis symptoms, and carers on the resumption of clinical research and adaptations to trials in light of COVID-19. Methods: An anonymous self-administered online survey was completed by 30 PD patients and six family members/carers via the Parkinson's UK Research Support Network to explore current perceptions on taking part in PD research and how a planned clinical trial for psychosis in PD may be adapted so participants feel safe. Results: Ninety-one percent of respondents were enthusiastic about the continuation of non-COVID-19 related research as long as certain safety measures were in place. Ninety-four percent stated that they would be happy to complete assessments virtually. However, they noted that care should be taken to ensure that this does not exclude participants, particularly those with more advanced PD who may require assistance using portable electronic devices. Regular and supportive communication from the research team was also seen as important for maintaining the psychological well-being of participants while taking part in the trial. Conclusions: In the era of COVID-19 pandemic, standard approaches will have to be modified and rapid adoption of virtual assessments will be critical for the continuation of clinical research. It is important that alongside the traditional methods, new tools are developed, and older ones validated for virtual assessments, to allow safe and comprehensive assessments vital for ongoing research in people with Parkinson's.

The clinical impact of COVID-19 infection on people with Parkinson's

The impact of COVID-19 has been, and continues to be, felt across the world. For some people the risks associated with contracting this virus are greater than others due to underlying health conditions. This article explores the impact of COVID-19 for people with Parkinson's and how specialist health services are having to change to continue to support this group of patients.

COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside.

This Viewpoint discusses insights from basic science and clinical perspectives on coronavirus disease 2019 (COVID-19)/severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection in the brain, with a particular focus on Parkinson's disease. Major points include that neuropathology studies have not answered the central issue of whether the virus enters central nervous system neurons, astrocytes or microglia, and the brain vascular cell types that express virus have not yet been identified. Currently, there is no clear evidence for human neuronal or astrocyte expression of angiotensin-converting enzyme 2 (ACE2), the major receptor for viral entry, but ACE2 expression may be activated by inflammation, and a comparison of healthy and infected brains is important. In contrast to the 1918 influenza pandemic and avian flu, reports of encephalopathy in COVID-19 have been slow to emerge, and there are so far no documented reports of parkinsonism apart from a single case report. We recommend consensus guidelines for the clinical treatment of Parkinson's patients with COVID-19. While a role for the virus in causing or exacerbating Parkinson's disease appears unlikely at this time, aggravation of specific motor and non-motor symptoms has been reported, and it will be important to monitor subjects after recovery, particularly for those with persisting hyposmia.